Aviado · Research
Longevity Daily
Saturday, October 3, 2026
Listen
Today's Brief
The longevity field reached a historic milestone this week as FDA officials publicly named aging a regulatory priority at ARDD 2026, signaling that anti-aging therapies may finally have a pathway to approval. This issue's must-read: a 130,000-person study finds that optimizing Life's Essential 10 metrics can add up to 9.73 years of disease-free life — making cardiovascular health the most powerful longevity lever most of us aren't treating seriously enough. Elsewhere, British scientists extend lifespan across three distinct species by directly activating AMPK, GLP-1 drugs emerge as credible brain protectors against Parkinson's and stroke, and a systematic review delivers a sobering reality check on NAD+ supplements.
10 stories3 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
GLP-1 Drugs May Protect Against Parkinson's and Stroke — Here's the Growing Evidence
A comprehensive review at NeurologyLive details the mounting case for repositioning GLP-1 receptor agonists — drugs like semaglutide — against neurological disease. A double-blind, placebo-controlled trial of 59 Parkinson's patients showed statistically significant improvement in motor function over 9 months (P=.001), and GLP-1 drugs appear to act on the brain through two distinct pathways: reducing vascular risk factors and potentially providing direct neuroprotection. If you've been following the semaglutide conversation for metabolic health, its brain-health implications are becoming impossible to ignore.
Read more →Nearly 1 in 5 People Who Have a 'Mini-Stroke' Develop Dementia Within 7 Years
A new study tracking patients with transient ischemic attack found that 19.3% developed dementia over a median follow-up of 7.11 years — with dementia rates consistently higher than matched controls at every measured time point. TIA is commonly dismissed as a 'warning stroke' because symptoms resolve quickly, but this data suggests the underlying brain injury may be far more lasting than previously appreciated. If you or a loved one has had a TIA, aggressive cognitive monitoring and vascular risk management are now strongly warranted.
Read more →Epigenetic Age Acceleration Predicts Future Memory Decline — New Evidence Builds
A new analysis finds that individuals with faster epigenetic aging — as measured by DNA methylation clocks — show significantly higher rates of later memory loss, reinforcing that these biomarkers may be capturing genuine biological processes that manifest in cognitive function decades later. The research is still correlational, and epigenetic clocks aren't yet reliable enough to drive individual treatment decisions, but the findings add meaningful weight to their use as early warning signals worth tracking over time.
Read more →Supplements & Compounds
Daily Creatine Preserves Muscle and Boosts Memory in Older Adults — Even Without Exercise
New research in the Journal of the International Society of Sports Nutrition links daily creatine supplementation to reduced body fat, preserved muscle mass, and improved cognitive function in middle-aged and older adults — including those who don't exercise. Texas A&M researchers wrote that the findings 'support contentions that creatine supplementation can help older individuals maintain muscle mass, strength, and cognitive function.' At a few dollars a month, creatine remains one of the most cost-effective interventions for the 60+ crowd.
Read more →NAD+ Supplements Show Biological Activity — But Clinical Benefits Remain Inconclusive
A recent systematic review found that NAD+ supplementation shows measurable biological activity — meaning your NMN or NR is likely raising blood NAD+ levels — but clinical effectiveness for anti-aging or wellness outcomes was inconclusive. Translation: the mechanism looks promising, but human trials haven't yet shown meaningful health improvements that justify the premium price point for most buyers. This isn't a reason to stop, but it's a useful reality check on one of the supplement world's most hyped categories.
Read more →L-Citrulline Can Drop Blood Pressure by 9 mmHg — But Only If You're the Right Person
Most people taking L-citrulline for cardiovascular support are wasting their money. Aviado Research's analysis of the human trial data reveals the amino acid works almost exclusively for specific groups: postmenopausal women with elevated blood pressure, older adults with arterial stiffness, and people whose pressure spikes in cold weather. If you fit one of these profiles, expect a 4–9 mmHg drop in systolic pressure within 8–12 weeks using 3,000–6,000 mg of pure L-citrulline daily — not the malate form. If you're a healthy adult with normal vascular function, the evidence suggests you'll see little to no benefit.
Read the full Aviado analysis →Research & Papers
Your Cardiovascular Health Score Could Unlock Up to 9.7 Extra Years of Disease-Free Life
A landmark study of more than 130,000 people across the UK Biobank and NHANES found that scoring high on Life's Essential 10 — a composite metric spanning sleep, mental health, alcohol, exercise, diet, weight, cholesterol, blood sugar, blood pressure, and smoking — was associated with a 57–66% lower risk of dying from any cause. At age 50, high-scorers gained an average of 5.5 extra years of total life expectancy and more than 4 disease-free years compared to low-scorers; across all low-risk factors combined, projected disease-free life expectancy gains reached nearly 10 years. LE10 extends the well-known Essential 8 framework by adding alcohol and mental health, giving readers two new optimization targets worth auditing today. This is large-scale, peer-reviewed human data — the kind that should change how you think about lifestyle as medicine.
Read more →British Scientists Extend Lifespan Across Three Species by Directly Targeting AMPK
Researchers have directly activated AMPK — the cellular energy sensor long associated with metformin's effects — and extended lifespan in yeast, worms, and fruit flies, marking what scientists call the first demonstration that pharmacologically targeting AMPK can produce longevity benefits in living organisms. Dr. Cochemé, who led the team, described the cross-species result as 'very exciting.' The critical caveat: no mouse or human data yet, so the leap to personal longevity protocols remains significant — but the findings sharpen the scientific case that AMPK is a genuine longevity target, not merely an interesting pathway.
Read more →Lifestyle & Nutrition
More Protein Isn't Always Better for Aging — Non-Essential Amino Acids May Be the Missing Piece
A new analysis via Medscape challenges the conventional wisdom that simply eating more protein is the key to healthy aging. Researchers concluded that non-essential amino acids (NEAAs) may be as important to the aging process as essential amino acids — and that supplementing some NEAAs could promote healthy aging, while reducing intake of others might also benefit longevity. This adds important nuance to the protein optimization conversation: the focus should shift from hitting a total gram target to examining the amino acid composition of your protein sources.
Read more →Industry & Policy
FDA Names Longevity a Regulatory Priority at ARDD 2026 — A Potential Turning Point for the Field
At a high-profile panel during the Aging Research & Drug Discovery (ARDD) 2026 conference in Boston, senior FDA officials announced plans to formally include aging in the agency's regulatory science agenda and outlined how aging therapies could be structured to move through the approval pipeline. Without a recognized regulatory pathway, even the most compelling anti-aging therapies have had nowhere to go — making this one of the most consequential policy developments in longevity medicine in years. Researchers, investors, and biotech founders should pay close attention.
Read more →